These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 26049551)

  • 1. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
    Sands AT; Zambrowicz BP; Rosenstock J; Lapuerta P; Bode BW; Garg SK; Buse JB; Banks P; Heptulla R; Rendell M; Cefalu WT; Strumph P
    Diabetes Care; 2015 Jul; 38(7):1181-8. PubMed ID: 26049551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
    Danne T; Cariou B; Buse JB; Garg SK; Rosenstock J; Banks P; Kushner JA; McGuire DK; Peters AL; Sawhney S; Strumph P
    Diabetes Care; 2019 May; 42(5):919-930. PubMed ID: 30833371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
    Buse JB; Garg SK; Rosenstock J; Bailey TS; Banks P; Bode BW; Danne T; Kushner JA; Lane WS; Lapuerta P; McGuire DK; Peters AL; Reed J; Sawhney S; Strumph P
    Diabetes Care; 2018 Sep; 41(9):1970-1980. PubMed ID: 29937430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
    Danne T; Pettus J; Giaccari A; Cariou B; Rodbard H; Weinzimer SA; Bonnemaire M; Sawhney S; Stewart J; Wang S; Castro RC; Garg SK
    Diabetes Technol Ther; 2019 Sep; 21(9):471-477. PubMed ID: 31335194
    [No Abstract]   [Full Text] [Related]  

  • 5. HbA
    Danne T; Cariou B; Banks P; Brandle M; Brath H; Franek E; Kushner JA; Lapuerta P; McGuire DK; Peters AL; Sawhney S; Strumph P
    Diabetes Care; 2018 Sep; 41(9):1981-1990. PubMed ID: 29937431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
    Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
    Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
    Pieber TR; Famulla S; Eilbracht J; Cescutti J; Soleymanlou N; Johansen OE; Woerle HJ; Broedl UC; Kaspers S
    Diabetes Obes Metab; 2015 Oct; 17(10):928-35. PubMed ID: 26080652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
    Shimada A; Hanafusa T; Yasui A; Lee G; Taneda Y; Sarashina A; Shiki K; George J; Soleymanlou N; Marquard J
    Diabetes Obes Metab; 2018 Sep; 20(9):2190-2199. PubMed ID: 29766633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m
    Danne T; Edelman S; Frias JP; Ampudia-Blasco FJ; Banks P; Jiang W; Davies MJ; Sawhney S
    Diabetes Obes Metab; 2021 Mar; 23(3):854-860. PubMed ID: 33289297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
    Garg SK; Henry RR; Banks P; Buse JB; Davies MJ; Fulcher GR; Pozzilli P; Gesty-Palmer D; Lapuerta P; Simó R; Danne T; McGuire DK; Kushner JA; Peters A; Strumph P
    N Engl J Med; 2017 Dec; 377(24):2337-2348. PubMed ID: 28899222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
    Musso G; Gambino R; Cassader M; Paschetta E
    BMJ; 2019 Apr; 365():l1328. PubMed ID: 30967375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy.
    Rosenstock J; Cefalu WT; Lapuerta P; Zambrowicz B; Ogbaa I; Banks P; Sands A
    Diabetes Care; 2015 Mar; 38(3):431-8. PubMed ID: 25216510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
    Danne T; Biester T; Kordonouri O
    Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
    Baker C; Wason S; Banks P; Sawhney S; Chang A; Danne T; Gesty-Palmer D; Kushner JA; McGuire DK; Mikell F; O'Neill M; Peters AL; Strumph P
    Diabetes Obes Metab; 2019 Nov; 21(11):2440-2449. PubMed ID: 31264767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
    Neal B; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Ways K; Desai M; Shaw W; Capuano G; Alba M; Jiang J; Vercruysse F; Meininger G; Matthews D;
    Diabetes Care; 2015 Mar; 38(3):403-11. PubMed ID: 25468945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin.
    Lapuerta P; Urbina S; He J; Wittle A; Li C; Li T; Wang H; Hompesch M
    Clin Pharmacol Ther; 2024 Jun; 115(6):1383-1390. PubMed ID: 38456487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
    Matthaei S; Bowering K; Rohwedder K; Grohl A; Parikh S;
    Diabetes Care; 2015 Mar; 38(3):365-72. PubMed ID: 25592197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
    Rosenstock J; Marquard J; Laffel LM; Neubacher D; Kaspers S; Cherney DZ; Zinman B; Skyler JS; George J; Soleymanlou N; Perkins BA
    Diabetes Care; 2018 Dec; 41(12):2560-2569. PubMed ID: 30287422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study.
    Posch MG; Walther N; Ferrannini E; Powell DR; Banks P; Wason S; Dahmen R
    Diabetes Care; 2022 Sep; 45(9):2118-2126. PubMed ID: 35817022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.